BeOne Medicines AG (06160.HK)

BeOne Medicines AG is a Switzerland-based company operating in the biotechnology industry. The company is headquartered in Basel, Basel-Stadt, and currently employs 11,075 full-time employees. It went public on March 2, 2016. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company dedicated to discovering and developing therapies for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the company is advancing a diverse pipeline of novel therapeutics. Its commercial products include Brukinsa, Tevimbra, and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting programmed cell death protein 1 (PD-1), featuring high affinity and binding specificity. Designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, Tevimbra helps the body’s immune cells recognize and combat tumors. The company’s clinical-stage pipeline includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.